Latest On ANI Pharmaceuticals, Inc (ANIP):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-31 02:07 EST | News | ANI Pharmaceuticals: Strong Revenue Growth And ANDA Approvals | N/A |  |
| 2023-05-15 20:53 EST | News | ANI Pharma gains as FDA clears generics for Celontin and Fosamax | N/A | |
| 2023-05-12 20:30 EST | News | ANI Pharmaceuticals down 6%, prices $75M offering | N/A | |
| 2023-05-12 06:14 EST | News | ANI Pharmaceuticals announces proposed stock offering, shares fall 6% after hours | N/A | |
| 2023-05-08 20:59 EST | News | ANI Pharmaceuticals soars ~10% after Q1 beat, raises outlook amid rare disease focus | N/A | |
About ANI Pharmaceuticals, Inc (ANIP):
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
General
- Name ANI Pharmaceuticals, Inc
- Symbol ANIP
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 369
- Last Split Factor1:6
- Last Split Date2013-07-18
- Fiscal Year EndDecember
- IPO Date2000-05-05
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.anipharmaceuticals.com
Valuation
- Trailing PE 77.58
- Forward PE 8.31
- Price/Sales (Trailing 12 Mt.) 1.75
- Price/Book (Most Recent Quarter) 1.84
- Enterprise Value Revenue 2.59
- Enterprise Value EBITDA 19.21
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $3.44
- Next Year EPS Estimate $4.43
- Next Quarter EPS Estimate $0.87
- Profit Margin -11%
- Operating Margin -2%
- Return on Assets -1%
- Return on Equity -11%
- Revenue 208.48 million
- Earnings Per Share $1.34
- Revenue Per Share $17.43
- Gross Profit 125.62 million
- Quarterly Earnings Growth 19.4%
Highlights
- Market Capitalization 408.05 million
- EBITDA 39.87 million
- PE Ratio 55.14
- PEG Ratio 1.06
- Analyst Target Price $38.33
- Book Value Per Share $16.31
Share Statistics
- Shares Outstanding 12.35 million
- Shares Float 9.25 million
- % Held by Insiders 474%
- % Held by Institutions 79.46%
- Shares Short 542783
- Shares Short Prior Month 521318
- Short Ratio 10.51
- Short % of Float 7%
- Short % of Shares Outstanding 4%
Technicals
- Beta 1.23
- 52 Week High $52.22
- 52 Week Low $23.55
- 50 Day Moving Average 30.62
- 200 Day Moving Average 29.54
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
ANI Pharmaceuticals, Inc (ANIP) Dividend Calendar:
ANI Pharmaceuticals, Inc (ANIP) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
ANI Pharmaceuticals, Inc (ANIP) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
ANI Pharmaceuticals, Inc (ANIP) Chart:
ANI Pharmaceuticals, Inc (ANIP) News:
Below you will find a list of latest news for ANI Pharmaceuticals, Inc (ANIP) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
ANI Pharmaceuticals, Inc (ANIP) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ANIP Trades:
ANI Pharmaceuticals, Inc (ANIP) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-05 | 8-K (Current report) | |
| 2020-09-10 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-09-10 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-07 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-07 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-07 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-07 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-08-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-03 | 8-K (Current report) | |
| 2020-07-17 | EFFECT (Notice of Effectiveness) | |
| 2020-07-16 | CORRESP (Correspondence) | |
| 2020-07-14 | UPLOAD (SEC-generated letter) | |
| 2020-07-09 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-06-11 | 8-K (Current report) | |
| 2020-06-11 | 8-K (Current report) | |
| 2020-06-01 | 8-K (Current report) | |
ANI Pharmaceuticals, Inc (ANIP) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of ANI Pharmaceuticals, Inc (ANIP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 474%
Institutional Ownership: 7946%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-08 | Nikhil Lalwani | PRESIDENT & CEO | Buy | 28,508.00 | 28,508.00 | | ||
| 2020-08-10 | Patrick D Walsh | CHAIRMAN, INTERIM PRES. & CEO | Buy | 3,000.00 | 30.40 | 91,200.00 | 23,096.00 | |
| 2020-08-10 | Patrick D Walsh | CHAIRMAN, INTERIM PRES. & CEO | Buy | 4,000.00 | 30.98 | 123,920.00 | 27,096.00 | |
| 2020-08-10 | Patrick D Walsh | CHAIRMAN, INTERIM PRES. & CEO | Buy | 3,000.00 | 30.89 | 92,670.00 | 30,096.00 | |
| 2020-08-05 | Antonio R Pera | Director | Buy | 7,421.00 | 7,421.00 | | ||
| 2020-08-05 | Jeanne Thoma | Director | Buy | 7,421.00 | 7,421.00 | | ||
| 2020-05-11 | Patrick D Walsh | Interim President and CEO | Buy | 7,050.00 | 20,096.00 | | ||
| 2020-04-10 | DAVID NASH | Director | Buy | 7,119.00 | 12,355.00 | | ||
| 2020-04-10 | Patrick D Walsh | Director | Buy | 9,255.00 | 13,046.00 | | ||
| 2020-04-10 | THOMAS HAUGHEY | Director | Buy | 7,119.00 | 18,410.00 | | ||
| 2020-04-10 | Robert E. JR Brown | Director | Buy | 7,119.00 | 29,680.00 | | ||
| 2020-04-10 | STEPHEN P. CAREY | Vice President and CFO | Buy | 39,767.00 | 63,145.00 | | ||
| 2020-04-10 | James G. Marken | SVP Ops & Prod Dev | Buy | 24,548.00 | 85,297.00 | | ||
| 2020-04-10 | Robert W Schrepfer | SVP - New Bus Dev & Spec Sales | Buy | 39,767.00 | 93,043.00 | | ||
| 2020-03-04 | THOMAS HAUGHEY | Director | Buy | 3,000.00 | 45.05 | 135,150.00 | 11,291.00 | |
| 2020-03-03 | THOMAS HAUGHEY | Director | Buy | 2,000.00 | 45.18 | 90,360.00 | 8,291.00 | |
| 2019-08-20 | VENTURE PARTNERS II LP MERIDIAN | 10% Share Holder | Sell | 5,512.00 | 68.18 | 375,808.16 | 2,219,259.00 | |
| 2019-08-19 | VENTURE PARTNERS II LP MERIDIAN | 10% Share Holder | Sell | 2,067.00 | 68.30 | 141,176.10 | 2,224,771.00 | |
| 2019-08-16 | VENTURE PARTNERS II LP MERIDIAN | 10% Share Holder | Sell | 26,349.00 | 68.09 | 1,794,103.41 | 2,226,838.00 | |
| 2019-08-15 | VENTURE PARTNERS II LP MERIDIAN | 10% Share Holder | Sell | 9,315.00 | 69.34 | 645,902.10 | 2,253,187.00 | |